Total Valuation
Orphazyme has a market cap or net worth of $4.44M. The enterprise value is $26.44M.
Market Cap$4.44M
Enterprise Value$26.44M
Share Statistics
Orphazyme has 41,712 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding41,712
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Orphazyme’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -13.30%.
Return on Equity (ROE)-0.05
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-13.30%
Return on Capital Employed (ROCE)-0.13
Revenue Per Employee309.00K
Profits Per Employee-859.00K
Employee Count1
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Orphazyme is ―. Orphazyme’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value1.58
Price to FCF0.00
Price to Operating Cash Flow11.55
PEG Ratio―
Income Statement
In the last 12 months, Orphazyme had revenue of 309.00K and earned -859.00K in profits. Earnings per share was -21.00.
Revenue309.00K
Gross Profit309.00K
Operating Income-2.45M
Pretax Income-859.00K
Net Income-859.00K
EBITDA-2.45M
Earnings Per Share (EPS)-21.00
Cash Flow
In the last 12 months, operating cash flow was 2.49M and capital expenditures 0.00, giving a free cash flow of 2.49M billion.
Operating Cash Flow2.49M
Free Cash Flow2.49M
Free Cash Flow per Share59.74
Dividends & Yields
Orphazyme pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.00
52-Week Price Change0.00%
50-Day Moving Average90.00
200-Day Moving Average90.00
Relative Strength Index (RSI)100.00
Average Volume (3m)0.00
Important Dates
Orphazyme upcoming earnings date is Sep 2, 2025, TBA (Confirmed).
Last Earnings DateFeb 28, 2025
Next Earnings DateSep 2, 2025
Ex-Dividend Date―
Financial Position
Orphazyme as a current ratio of 13.90, with Debt / Equity ratio of 0.00%
Current Ratio13.90
Quick Ratio13.90
Debt to Market Cap0.00
Net Debt to EBITDA0.16
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Orphazyme has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Orphazyme EV to EBITDA ratio is -11.74, with an EV/FCF ratio of -13.45.
EV to Sales92.95
EV to EBITDA-11.74
EV to Free Cash Flow-13.45
EV to Operating Cash Flow-13.45
Balance Sheet
Orphazyme has $15.93M in cash and marketable securities with ― in debt, giving a net cash position of $15.93M billion.
Cash & Marketable Securities$15.93M
Total Debt―
Net Cash$15.93M
Net Cash Per Share$381.78
Tangible Book Value Per Share$440.88
Margins
Gross margin is 100.00%, with operating margin of -791.59%, and net profit margin of -277.99%.
Gross Margin100.00%
Operating Margin-791.59%
Pretax Margin-277.99%
Net Profit Margin-277.99%
EBITDA Margin-791.59%
EBIT Margin-791.59%
Analyst Forecast
The average price target for Orphazyme is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-150.13%